Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,92
KB2,59
PKN130,3130,48-2,83
Msft372,24372,280,57
Nokia6,967,1445,48
IBM245,66245,751,37
Mercedes-Benz Group AG52,8852,860,94
PFE28,2628,270,66
01.04.2026 17:56:54
Indexy online
AD Index online
select
AD Index online
 

  • 01.04.2026 17:51:44
Landec Corp (LNDC.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
3,85 3,36 0,13 401 944
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.04.2026
Popis společnosti
Obecné informace
Název společnostiLifecore Biomedical Inc
TickerLFCR
Kmenové akcie:Ordinary Shares
RICLFCR.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2025
Poslední známé čtvrtletní výsledky31.12.2025
Počet zaměstnanců k 31.12.2025 382
Akcie v oběhu k 31.12.2025 37 477 386
MěnaUSD
Kontaktní informace
Ulice3515 Lyman Boulevard
MěstoCHASKA
PSČ55318
ZeměUnited States
Kontatní osobaStephanie Diaz
Funkce kontaktní osobyInvestor Relations
Telefon19 523 684 300
Fax13026365454
Kontatní telefon14 156 757 401

Business Summary: Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization that provides services in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes, vials and cartridges. It manufactures pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) using fermentation-based HA process. It manufactures HA in bulk form and for use in formulated and filled syringes and vials for our customers’ injectable products used in treating medical conditions and procedures, including ophthalmic and orthopedic applications. Its product development service capabilities include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation and production of materials for clinical studies. It also operates semi-automated restricted access barrier systems (RABS) and fully automated aseptic filling lines with isolators.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Lifecore Biomedical Inc revenues totaled $75.5M. Net loss applicable to common stockholders totaled to $20.1M. Results are not comparable due to year end change.
Odvětvová klasifikace
TRBC2009Chemicals - Specialty
TRBC2012Pharmaceuticals (NEC)
RBSS2004Chemicals - Specialty
MGINDUSTRYFood Processing
MGSECTORConsumer/Non-Cyclical
NAICSFats and Oils Refining and Blending
NAICSPharmaceutical Preparation Manufacturing
NAICSOther Chemical and Allied Products Merchant Wholesalers
NAICSGrain and Field Bean Merchant Wholesalers
NAICSAdhesive Manufacturing
NAICSPlastics Material and Resin Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSFruit and Vegetable Canning
NAICSPerishable Prepared Food Manufacturing
NAICSFrozen Fruit, Juice, and Vegetable Manufacturing
NAICS2007Perishable Prepared Food Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007All Other Basic Inorganic Chemical Mfg
NAICS1997Perishable Prepared Food Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997All Other Basic Inorganic Chemical Manufacturing
SICPlastics Materials And Resins
SICPharmaceutical Preparations
SICEdible Fats And Oils, Nec
SICChemicals & Allied Products, Nec
SICGrain And Field Beans
SICAdhesives And Sealants
SICPlastics Materials And Resins
SICCommercial Physical Research
SICCanned Fruits And Vegetables
SICFood Preparations, Nec
SICFrozen Fruits And Vegetables



  • Poslední aktualizace: 01.04.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorPaul Josephs6020.05.202420.05.2024
Chief Financial OfficerRyan Lake4703.09.202403.09.2024
Chief Legal and Administrative Officer , SecretaryThomas Salus5614.04.202514.04.2025